Globestar Therapeutics CORP
Market Movers (8-K)
OTC.Pink
GlobeStar Therapeutics Corporation announced the resignation of its Chief Financial Officer, Robert Chicoski, effective August 8, 2024.
Quarterly Earnings (10-Q)
OTC.Pink
GlobeStar Therapeutics reports a net loss for Q3 2024 and announces a shift in business focus away from Multiple Sclerosis treatments.
Worse than expected
Capital raise
OTC.Pink
GlobeStar Therapeutics Corporation reported a net loss of $338,721 for the six months ended March 31, 2024, and is actively seeking additional financing to continue operations.
Worse than expected
Capital raise
OTC.Pink
GlobeStar Therapeutics Corporation reports no revenue and a net loss of $163,759 for the quarter ended December 31, 2023, with substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
Annual Reports (10-K)
OTC.Pink
10-K: GlobeStar Therapeutics Corporation Files 10-K Annual Report, Outlines Path Forward for MS Treatment
GlobeStar Therapeutics Corporation has filed its annual report on Form 10-K for the fiscal year ended September 30, 2023, detailing its financial status and strategic initiatives, particularly in the development of a patented multiple sclerosis treatment.
Capital raise
Worse than expected